TILT Holdings Targets ‘Every Stage Of The Cannabis Supply Chain’ With M&A Strategy

TILT Holdings Inc (OTC: SVVTF), which has amassed businesses primarily focused on providing B2B solutions, is an example of a cannabis company with operations in both Canada and the U.S.  Continue reading “TILT Holdings Targets ‘Every Stage Of The Cannabis Supply Chain’ With M&A Strategy”

Pain, Pain, Go Away: Cannabis and the Medical Consumer

America is in pain. In fact, according to the National Institutes of Health, among all U.S. adults, nearly 40 million (17.6%) report suffering from severe pain, while about 25.3 million (11.2%) complained of experiencing daily pain throughout the previous three months. Continue reading “Pain, Pain, Go Away: Cannabis and the Medical Consumer”

Analysts: Altria And Cronos Make A Good Team

Tobacco giant Altria Group Inc. (NYSE: MO) is interested in a buyout of Canadian cannabis company Cronos Group, Inc. (NASDAQ: CRON). Wall Street analysts see Altria and Cronos as a compelling team. Continue reading “Analysts: Altria And Cronos Make A Good Team”

Canopy Growth’s Global Opportunity Could Reach $200B, Benchmark Says In Bullish Initiation

Shares of cannabis and hemp company Canopy Growth Corp. (NYSE: CGC) have doubled since the stock began trading on the New York Stock Exchange back in May. Continue reading “Canopy Growth’s Global Opportunity Could Reach $200B, Benchmark Says In Bullish Initiation”

GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)’s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch. Continue reading “GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis”

Investing In Marijuana: Cannabis Industry Raises Hit $1.8 Billion, Up 150% Year Over Year

Despite strong opposition from former White House Press Secretary Sean Spicer and Attorney General Jeff Sessions, and the overall limitations imposed by federal illegality in the U.S., 2017 is shaping up to be a great year for the North American cannabis in Continue reading “Investing In Marijuana: Cannabis Industry Raises Hit $1.8 Billion, Up 150% Year Over Year”

What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial Continue reading “What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals”

GW Pharma Takes A Step Toward Diversifying

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Continue reading “GW Pharma Takes A Step Toward Diversifying”

Marijuana Legalization Around The World: Who’s Next?

On Tuesday, Benzinga published an article where cannabis industry experts shared their thoughts regarding the legalization of recreational marijuana in Canada. But, America’s hat is not the only country considering legalization measures. Continue reading “Marijuana Legalization Around The World: Who’s Next?”